Trial · NCT02791763
Results by group407
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 407
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND Participants | Daprodustat in ND Participants | 11.97 | Standard Error 0.061 | Grams per deciliter (g/dL) | |
| Mean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND Participants | Epoetin Beta Pegol in ND Participants | 11.86 | Standard Error 0.063 | Grams per deciliter (g/dL) | |
| Number of ND Participants With Mean Hgb in the Target Range (11.0-13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) | Daprodustat in ND Participants | Responder | 81 | Participants | |
| Number of ND Participants With Mean Hgb in the Target Range (11.0-13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) | Epoetin Beta Pegol in ND Participants | Responder | 80 | Participants | |
| Number of ND Participants With Mean Hgb in the Target Range (11.0-13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) | Daprodustat in ND Participants | Non-Responder | 7 | Participants | |
| Number of ND Participants With Mean Hgb in the Target Range (11.0-13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) | Epoetin Beta Pegol in ND Participants | Non-Responder | 7 | Participants | |
| Percentage of ND Participants With Mean Hgb in the Target Range (11.0-13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) | Daprodustat in ND Participants | Responder | 92 | Percentage of participants | |
| Percentage of ND Participants With Mean Hgb in the Target Range (11.0-13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) | Epoetin Beta Pegol in ND Participants | Responder | 92 | Percentage of participants | |
| Percentage of ND Participants With Mean Hgb in the Target Range (11.0-13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) | Daprodustat in ND Participants | Non-Responder | 8 | Percentage of participants | |
| Percentage of ND Participants With Mean Hgb in the Target Range (11.0-13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) | Epoetin Beta Pegol in ND Participants | Non-Responder | 8 | Percentage of participants | |
| Change From Baseline in Hgb at Week 4 in ND Participants | Daprodustat in ND Participants | 0.47 | Standard Deviation 0.878 | g/dL | |
| Change From Baseline in Hgb at Week 4 in ND Participants | Epoetin Beta Pegol in ND Participants | 0.26 | Standard Deviation 0.711 | g/dL | |
| Change From Baseline in Hgb at Week 4 in PD Participants | Daprodustat in PD Participants | -0.09 | Standard Deviation 0.899 | g/dL | |
| Number of ND Participants by Hgb Change From Baseline Category at Week 4 | Daprodustat in ND Participants | <=-2.0 | 1 | Participants | |
| Number of ND Participants by Hgb Change From Baseline Category at Week 4 | Epoetin Beta Pegol in ND Participants | <=-2.0 | 2 | Participants | |
| Number of ND Participants by Hgb Change From Baseline Category at Week 4 | Daprodustat in ND Participants | >-2.0 and <=-1.0 | 4 | Participants | |
| Number of ND Participants by Hgb Change From Baseline Category at Week 4 | Epoetin Beta Pegol in ND Participants | >-2.0 and <=-1.0 | 3 | Participants | |
| Number of ND Participants by Hgb Change From Baseline Category at Week 4 | Daprodustat in ND Participants | >-1.0 and <=0 | 28 | Participants | |
| Number of ND Participants by Hgb Change From Baseline Category at Week 4 | Epoetin Beta Pegol in ND Participants | >-1.0 and <=0 | 33 | Participants | |
| Number of ND Participants by Hgb Change From Baseline Category at Week 4 | Daprodustat in ND Participants | >0 and <=1.0 | 43 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02791763/results